Are you a financial expert?Login
FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors
Signup

ASTRAZEN

3,535.95
-1.3 (-0.04%)
Updated 09:20 07/07 IST

ASTRAZEN Buy or Sell - FrontPage Forums

0 Users have submitted 0 trade ideas of Rs. 0 for ASTRAZEN
Disclaimer
0% Bullish
0% Bearish

ASTRAZEN Buy or Sell - Brokerage Reports

No. of reports in last year
0
No. of analysts
0
Average Consensus Forecast
Consensus Potential
0.00%
See ASTRAZEN Share Price Targets >>

ASTRAZEN Ratings

Long term ASTRAZEN rating by FrontPage users
  • ★
    ★
  • ★
    ★
  • ★
    ★
  • ★
    ★
  • ★
    ★
0/5 (0 Ratings)0
Find answers to all your questions on live ASTRAZEN message board: Is ASTRAZEN buy or sell? Should I buy ASTRAZEN shares? Why are ASTRAZEN shares falling? Should I invest in ASTRAZEN stock?

  1. Home
  2. ASTRAZEN Forum

ASTRAZEN Share Price Discussion

P
PRIT PATEL  @pritpatel
Reputation: -475 • Yesterday 3:06 AM
Astrazeneca Pharma India is currently trading at Rs. 3552.40, up by 40.45 points or 1.15% from its previous closing of Rs. 3511.95 on the BSE.

The scrip opened at Rs. 3570.00 and has touched a high and low of Rs. 3570.00 and Rs. 3545.90 respectively.

The BSE group 'A' stock of ...
Read more...
Like
Reply
N
NewsBot @newsbot
Reputation: 3,853 • Yesterday 1:01 AM
Stocks in the news: Reliance Ind, ICICI Bank, Indiabulls Housing, YES Bank, Biocon and NBCC
Lupin, Marksans Pharma, Aurobindo Pharma and Alembic Pharmaceuticals are recalling products in the US market.
The Economic Times
Like
Reply
N
NewsBot @newsbot
Reputation: 3,853 • Jul 4 12:53 PM
AstraZeneca's Dapagliflozin gets DCGI nod for treatment of heart failure patients
The company has received import and market permission from DCGI in Form CT-20 (Marketing Authorisation- Additional Indication).
Moneycontrol
Like
Reply
A
Ankush Deshpande @ankushdeshpande
Reputation: 3,612 • Jun 29 8:51 AM
Type
Buy
Instrument
ASTRAZEN
Entry Price
₹3,640  ₹3,647.35
Price@Trade
₹3,636.15
Target Price
₹3,800
Stop Price
₹3,540
Valid Till
Jun 30, 2020 3:20 AM
Margin
₹364,735 approx for 100 Qty
Status
Exited before entry
#ASTRAZEN
Like
Reply (2)
Latest replies
Ankush Deshpande @ankushdeshpande
•
Jun 29 8:51 AM
Update
Entry Price Modified
Price @ Update
₹3,647.35
Original Entry Price
₹3,640
New Entry Price
₹3,647.35
Ankush Deshpande @ankushdeshpande
•
Jun 29 8:52 AM
Update
Exited before entry
Price @ Update
₹3,636.9
N
NewsBot @newsbot
Reputation: 3,853 • Jun 26 5:26 AM
The four front runners of the race for Covid vaccine
The vaccines for the deadly Covid-19 are in various stages of trial. ET takes a look at four vaccine candidates, where the results of the current stages of trials are expected to be out in July:
The Economic Times
Like
Reply
M
MAHESH MAKWANA @maheshmakwana
Reputation: -6,620 • Jun 25 2:58 AM
Type
Sell
Instrument
ASTRAZEN
Entry Price
₹3,380  ₹3,375.05
Price@Trade
₹3,376.7
Target Price
₹3,300
Stop Price
₹3,450
Valid Till
Jun 25, 2020 3:20 AM
Margin
₹168,752.5 approx for 50 Qty
Status
Exited
Exit Price
₹3,344.45
Net P&L
+₹1,530 (+0.91%)
#ASTRAZEN
Like
Reply (3)
Latest replies
MAHESH MAKWANA @maheshmakwana
•
Jun 25 2:59 AM
Update
Entry Price Modified
Price @ Update
₹3,375.05
Original Entry Price
₹3,380
New Entry Price
₹3,375.05
TrackerBot @trackerbot
•
Jun 25 2:59 AM
Update
Trade Entered
Entry Price
₹3,375.05
MAHESH MAKWANA @maheshmakwana
•
Jun 25 8:22 AM
Update
Exited
Exit Price
₹3,344.45
Net P&L
+₹1,530 (+0.91%)
N
NewsBot @newsbot
Reputation: 3,853 • Jun 24 5:56 AM
Brazil tests covid-19 shot, without deal to use it if it works
Brazil is testing an experimental coronavirus vaccine, but interim Health Minister Eduardo Pazuello acknowledged Tuesday that the government has yet to strike a deal to get it if it works. Other nations have already secured hundreds of millions of doses of the shot created by Oxford University.
The Economic Times
Like
Reply
N
NewsBot @newsbot
Reputation: 3,853 • Jun 24 3:31 AM
Cyrus Poonawalla enters top 100 rich-list, his wealth grows fifth fastest in the world during coronavirus pandemic
The Serum boss climbed 57 places to be the 86th richest person in the world.
The Economic Times
Like
Reply
N
NewsBot @newsbot
Reputation: 3,853 • Jun 21 2:36 AM
Wall Street expects a Covid-19 vaccine before US presidential election
Top virus expert Anthony Fauci, have set their eyes on a vaccine by early 2021 at the earliest
The Economic Times
Like
Reply
N
NewsBot @newsbot
Reputation: 3,853 • Jun 18 9:36 AM
EU in advanced talks with Johnson & Johnson on COVID-19 vaccine deal: Sources
The move would be the first arranged by the European Union executive since it was mandated last week by the 27 EU national governments to use an emergency fund with more than 2 billion euros ($2.3 billion) available to reach advance purchase or call-option deals with up to six vaccine makers.
The Economic Times
Like
Reply
N
NewsBot @newsbot
Reputation: 3,853 • Jun 16 7:41 AM
AstraZeneca COVID-19 vaccine likely to protect for a year: CEO
AstraZeneca said on Saturday that it had signed contracts with France, Germany, Italy and the Netherlands to supply the European Union with up to 400 million doses of the potential vaccine.
The Economic Times
Like
Reply
N
NewsBot @newsbot
Reputation: 3,853 • Jun 14 5:01 AM
AstraZeneca agrees to make COVID-19 vaccine for Europe
AstraZeneca plans to begin delivering the vaccine to European countries by the end of this year under the agreement with the Inclusive Vaccine Alliance, formed this month by France, Germany, Italy and the Netherlands.
The Economic Times
Like
Reply
N
NewsBot @newsbot
Reputation: 3,853 • Jun 14 1:46 AM
Second wave fears as China reports most new cases in months
The shock resurgence in domestic infections has rattled China where the disease emerged late last year but had largely been tamed through severe restrictions on movement that were later emulated across the globe.
The Economic Times
Like
Reply
N
NewsBot @newsbot
Reputation: 3,853 • Jun 13 12:56 PM
Covid-19: A cure still elusive, but science may find a way
India continues to see new cases and is one of the few countries to witness a rise after substantially relaxing lockdown restrictions. Scientists at drug and vaccine companies are making all efforts towards finding a cure for the pandemic.
The Economic Times
Like
Reply
G
Great Eagle Analysis  @greateagleta
Reputation: 4,576 • Jun 9 3:17 AM
ASTRAZEN - chart - 883216
#ASTRAZEN BUY MODE TGT 3594/3836/4144/4523 SL 2870
1
Reply
N
NewsBot @newsbot
Reputation: 3,853 • Jun 9 3:06 AM
Serum Institute investing USD 100 million on potential COVID-19 vaccine
"Our manufacturing facility is ready and we plan to start production in two months. We are spending more than USD 100 million for this facility. Till the trials are completed successfully for safety and efficacy, vaccines will not be distributed either in India or anywhere else in the world," Adar Poonawalla, CEO, SII, said.
The Economic Times
Like
Reply
N
NewsBot @newsbot
Reputation: 3,853 • Jun 8 7:46 AM
European stock rally takes step back as tech, healthcare drag
The pan-European STOXX 600 declined 0.4%, as investors moved out of expensive names, while bidding up laggards such as banking, auto and oil & gas stocks.
The Economic Times
Like
Reply
N
NewsBot @newsbot
Reputation: 3,853 • Jun 8 4:56 AM
Share market update: 37 stocks hit 52-week highs on NSE
​Benchmark NSE Nifty index was trading 161.85 points up at 10304.00.
The Economic Times
Like
Reply
N
NewsBot @newsbot
Reputation: 3,853 • Jun 7 8:21 AM
Sebi censures Astrazeneca Pharma's promoter, Elliot Group
Reason: professional misconduct and unfair trade practises during delisting plan in 2014.
The Economic Times
Like
Reply
N
NewsBot @newsbot
Reputation: 3,853 • Jun 7 7:51 AM
AstraZeneca approaches Gilead about potential merger
AstraZeneca, valued at $140 billion, is the U.K.s biggest drugmaker by market capitalization and has developed treatments for conditions from cancer to cardiovascular disease. Gilead, worth $96 billion at Fridays close, is the creator of a drug thats received U.S. approval for use with coronavirus patients.
The Economic Times
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 50,000 Indian traders and discuss trades, strategies, news & views on any stock.
Join FrontPage

  • ASTRAZEN - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization4,995.75
    Enterprise Value4,822.45
    Price to Earnings89.09
    Price to Book Value16.6
    Return on Capital Employed0.18
    Return on Equity0.11
    Face Value2
    Dividend YieldNA

  • ASTRAZEN - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    30-Nov-17Rudra Shares & Stocks BrokersBuy1,420
    ASTRAZEN Brokerage Price Target

  • ASTRAZEN Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jul 63539.93566.43505.953537.25
    Jul 3356935693488.453513.65
    Jul 23590.25359934803542.2
    Jul 135553588.134703552.4
    Jun 303646.25367035263547.7

  • ASTRAZEN Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹3,406.27
    30 Day Moving Average₹3,302.02
    50 Day Moving Average₹3,193.15
    100 Day Moving Average₹2,851.73
    200 Day Moving Average₹2,679.23

  • ASTRAZEN - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue571539.570.06
    Operating Profit4629.380.57
    Profit Before Tax4433.20.33
    Net Income2624.440.06

  • ASTRAZEN - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds3012470.22
    Total Liabilities2612150.21
    Total Assets5624620.22

  • ASTRAZEN - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity938.31-0.77
    Cash from Investing Activity-90.25-37
    Cash from Financing ActivityNA-0.22-1
    Net Cash Flow-138.35-1.03

  • ASTRAZEN - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.060.06
    Return on Equity0.110.14
    Return on Capital Employed0.180.18

  • ASTRAZEN - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.1
    3 Year CAGR Growth in Operating Profit5.03
    3 Year CAGR Growth in EBIDTA11.61
    3 Year CAGR Growth in Net Income2.25
    3 Yr CAGR Growth - Diluted EPS2.26

  • ASTRAZEN - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue0.46
    5 Year CAGR Growth in Operating Profit1.67
    5 Year CAGR Growth in EBIDTA2.02
    5 Year CAGR Growth in Net Income1.29
    3 Yr CAGR Growth - Diluted EPS1.29

  • ASTRAZEN - Recent News

    keyboard_arrow_down
    NewsBot
    Yesterday 1:01 AM
    Stocks in the news: Reliance Ind, ICICI Bank, Indiabulls Housing, YES Bank, Biocon and NBCC
    The Economic Times
    NewsBot
    Jul 4 12:53 PM
    AstraZeneca's Dapagliflozin gets DCGI nod for treatment of heart failure patients
    Moneycontrol
    NewsBot
    Jun 26 5:26 AM
    The four front runners of the race for Covid vaccine
    The Economic Times
    NewsBot
    Jun 24 5:56 AM
    Brazil tests covid-19 shot, without deal to use it if it works
    The Economic Times
    NewsBot
    Jun 24 3:31 AM
    Cyrus Poonawalla enters top 100 rich-list, his wealth grows fifth fastest in the world during coronavirus pandemic
    The Economic Times
    NewsBot
    Jun 21 2:36 AM
    Wall Street expects a Covid-19 vaccine before US presidential election
    The Economic Times
    NewsBot
    Jun 18 9:36 AM
    EU in advanced talks with Johnson & Johnson on COVID-19 vaccine deal: Sources
    The Economic Times
    NewsBot
    Jun 16 7:41 AM
    AstraZeneca COVID-19 vaccine likely to protect for a year: CEO
    The Economic Times
    NewsBot
    Jun 14 5:01 AM
    AstraZeneca agrees to make COVID-19 vaccine for Europe
    The Economic Times
    NewsBot
    Jun 14 1:46 AM
    Second wave fears as China reports most new cases in months
    The Economic Times

  • ASTRAZEN - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Apollo Hospitals Enterprise Ltd. NSE:...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.
Privacy•Terms•••
FrontPage © 2020